Products

Enviar

Create beautiful real estate landing pages in 30 seconds

enviar.io Marketing / Website & Landing Page Builders

Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Unknown
No monthly subscription pricing
Creators
Unlinked
No verified creators
Launched
8y ago
2017-12-05 · Est.

Traffic

Monthly visitsData through Oct 2026

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on Show HN (1 pts · 1 comments)Launch

    Re: enviar.io – Drop dead gorgeous websites for RE pros

    Jun 3, 2019 · 7y agoLaunch page

  • Launched on Product HuntLaunch

    Create beautiful real estate landing pages in 30 seconds

    Dec 7, 2017 · 8y agoLaunch page

  • Launched on Show HN (56 pts · 51 comments)Launch

    Enviar.io – Real estate landing pages

    Dec 6, 2017 · 8y agoLaunch page

  • Launched on Show HN (2 pts · 1 comments)Launch

    Enviar.io – Beautiful real estate landing pages in under 30 seconds

    Dec 5, 2017 · 8y agoLaunch page

Traffic sources

Oct 2026

Traffic breakdown

Channels

No data yet

Countries

No data yet

Search

Domain authority —Domain registered 2022-02-13

No search keyword data for this website yet.

Traffic data: Vaneform

Pricing

Pricing page not identified yet, or no public pricing listed.

Website snapshots

Indexed 2017-12-07

Key pages

Desktop & mobile archive

Website snapshots pending capture.

Questions & evidence

How much website traffic does Enviar get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is Enviar and what platforms does it support?
Enviar is catalogued under Website & Landing Page Builders: Create beautiful real estate landing pages in 30 seconds. Supported platforms: Web.

Related products in this category

Marketing / Website & Landing Page Builders

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.